



FOR IMMEDIATE RELEASE

**Patients Enrollment Completed in Clinical Study on
Trazodone Hydrochloride Tablets for Depression**

(Hong Kong 27th June 2013) – Lee's Pharmaceutical Holdings Limited (Main Board Stock: 0950: Website: www.leespharm.com) today announced that the Group has successfully completed the patient enrollment of Trazodone registration study in China. Trazodone (Trittico®) is a product licensed from Angelini of Italy and the registration study is to evaluate the efficacy and safety of Trazodone for treatment of depression in Chinese population.

This multi-centers, randomized, double-blind, parallel-group and placebo-controlled clinical study was conducted at 13 clinical centers located in Changsha, Beijing, Shanghai, Nanjing, Hangzhou, Tianjin and Guangzhou etc; and led by The Second Xiangya Hospital of Central South University in Changsha, Hunan. The targeted enrollment is 378 patients with the enrollment initiated in March 2012, and the last patient recruited to date.

"We are pleased to have reached this important milestone in the Trazodone study. We would like to thank the dedicated clinical investigators, study coordinators and patients who participated in our study as well as the support from Angelini," said Dr. Benjamin Li, Chief Executive Officer of the Company. "Depression prevalence has been increased significantly in China during the last 20 years. With Trittico®, Lee's will be positioned itself as an important player in a fast growing depression market in China."

Trazodone, a potent postsynaptic serotonin 5-HT_{2A} receptor antagonist and a moderate inhibitor of serotonin reuptake, is the original member of the SARIs (serotonin-2 antagonist/reuptake inhibitors) group of antidepressants. The targeted indication is depression with or without anxiety, including sleep disorders in depressed patients. The product has been widely prescribed since its original launch in 1990's by its originator Angelini. Trittico® is a sustained-release formulation newly developed by Angelini with better patient compliance.

The Group is expected to have the study report ready in September and subsequent filing of marketing authorization in October 2013.



FOR IMMEDIATE RELEASE

About Angelini

Angelini, a privately owned, international group with Italian roots, is leader in the healthcare and wellbeing market in the pharmaceutical and mass market sectors. Angelini was founded in Italy at the beginning of the 20th Century. It is a medium-sized group with branches in 18 countries and worldwide product distribution. In the pharmaceutical sector, Angelini focuses mainly on pain relief, inflammation, CNS, paediatrics, cold & flu, oralcare & sorethroat, gynecology, disinfection. Angelini is one of the top four pharmaceutical companies in Italy by sales volume. Today the Angelini Group, led by its chairman Francesco Angelini, the founder's grandson, is a major international corporation operating both in Italy and abroad and employing around 3,300 people, with total annual sales of approximately 1,2 billion euros.

About Lee's Pharmaceutical

Lee's Pharmaceutical Holdings Limited is a research-based Hong Kong biopharmaceutical company with over 19 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharmaceutical is available at www.leespharm.com.

Safe Harbor Statement

The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com